Understanding drug resistance in tuberculosis treatments in South Africa
Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa
This study is looking at how some people with tuberculosis in South Africa might develop resistance to new medications like bedaquiline, pretomanid, and linezolid, so we can better understand how these drugs work and help improve treatment for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10977076 on NIH RePORTER |
What this research studies
This research investigates how resistance to new tuberculosis medications, specifically bedaquiline, pretomanid, and linezolid, develops in patients undergoing treatment in South Africa. By observing patients receiving these drugs, the study aims to identify patterns of drug resistance that may emerge as these treatments become more widely used. The research will involve collecting data on patient outcomes and the genetic changes in the tuberculosis bacteria over time, helping to understand the dynamics of drug resistance in real-world settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with drug-resistant tuberculosis who are starting treatment with bedaquiline, pretomanid, or linezolid.
Not a fit: Patients with drug-sensitive tuberculosis or those not receiving the specified treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for drug-resistant tuberculosis, enhancing cure rates and patient outcomes.
How similar studies have performed: Previous research has shown that understanding drug resistance patterns can significantly improve treatment outcomes, indicating that this approach has potential for success.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Mathema, Barun — Columbia University Health Sciences
- Study coordinator: Mathema, Barun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.